American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer

Population-Based Cervical Screening Outcomes in Turkey over a Period of Approximately Nine and a Half Years with Emphasis on Results for Women Aged 30-34

“…It means for the present study that our rate of abnormal cytology of the women aged between 30-34, constituting 9.5% of the whole abnormal result, would be excluded according to previous standarts for the screening of cervical cancer. Besides, Saslow et al (2012) offered no screening before aged 21; cytology alone every 3 year for aged between 21-29; HPV and cytology "cotesting" every 5 year (preferred), cytology alone every 3 year (acceptable) for aged between 30-65; no screening following adequate negative prior screening after aged 65 as a summary of recommendations of American Cancer Society (ACS); American Society for Colposcopy and Cervical Pathology (ASCCP), and American Society for Clinical Pathology (ASCP) screening guidelines for the prevention and early detection of cervical cancer.…”

Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium

“…33 The act also funded public education designed to increase public awareness of the benefits of early detection, which may contribute to timely follow-up by patients with screening abnormalities.…”

Cervical Cancer Screening for Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians

“…2 In a recent survey, only 29 % of obstetrician-gynecologists felt comfortable caring for patients on the FTM spectrum, and 11 % were unwilling to perform routine Pap tests on FTM patients. 2 Advances in screening for cervical cancer [3][4][5] have reduced the frequency with which routine pelvic examinations are recommended for asymptomatic non-pregnant patients with female reproductive organs. 6 Nevertheless, periodic pelvic examinations are indicated for cervical cancer screening [3][4][5] in eligible transgender and cisgender patients regardless of symptoms, and are important in evaluating gynecological complaints.…”